|
|
|
|
Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
_ Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma.
New England Journal of Medicine:
Jun 25 2009 1:26PM
Matching: lymphoma large cell diffuse
|
Find similar documents
|
|
|
|
Seattle Genetics Initiates Phase II Trial Of SGN-35 For Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc.(NASDAQ:SGEN), announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug...
|
|
|
Seattle Genetics Initiates Phase II Trial Of SGN-35 For Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc.(NASDAQ:SGEN), announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
ADMET.net| BioInformatics.net | ClinicalTrials.net | CombiChem.net | ePosters.net | GenomicsNews.com | HighThroughputExperimentation.com | HTScreening.net | Lab-on-a-Chip.com | MarketReports.com | MassSpec.net | Metabolomics.net |...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- today announced that Dr.Heman Chao, chief scientific officer at , will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
- Seattle Genetics, Inc.(NASDAQ:SGEN), today announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
ADMET.net| BioInformatics.net | ClinicalTrials.net | CombiChem.net | ePosters.net | GenomicsNews.com | HighThroughputExperimentation.com | HTScreening.net | Lab-on-a-Chip.com | MarketReports.com | MassSpec.net | Metabolomics.net |...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
- Seattle Genetics, Inc.(NASDAQ:SGEN), today announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc.(NASDAQ:SGEN), today announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc.(NASDAQ: SGEN), today announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma...
|
|
|
Seattle Genetics Initiates Phase II Trial Of SGN-35 For Patients With Anaplastic Large Cell Lymphoma - Quick F
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Seattle Genetics, Inc.(SGEN: News ) said it commenced phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma, or ALCL....
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
We have observed promising activity in ALCL patients in our phase I trials, notably six out of seven patients treated with SGN-35 have achieved a complete response, said Clay B.Siegall, Ph. D., President and Chief Executive Officer of...
|
|
|
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large
Seattle Genetics, Inc.(NASDAQ:SGEN), today announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody...
|
|
|
Cancer-stricken Texas girl's wish: to wear a star
A sheriff's boots are big to fill, but 5-year-old Delaney Starcher was certainly willing to try them on her tiny feet Saturday.Harris County Sheriff Adrian Garcia presented the little girl, who has a rare, terminal form of brain cancer,...
|
|
|
Cancer-stricken Spring girls wish: to wear a star
A sheriffs boots are big to fill, but 5-year-old Delaney Starcher was certainly willing to try them on her tiny feet Saturday.Harris County Sheriff Adrian Garcia presented the little girl, who has a rare, terminal form of brain cancer,...
|
|
|
Cancer-stricken Spring girls wish: to wear a star
A sheriffs boots are big to fill, but 5-year-old Delaney Starcher was certainly willing to try them on her tiny feet Saturday.Harris County Sheriff Adrian Garcia presented the little girl, who has a rare, terminal form of brain cancer,...
|
|
|
Everolimus Enters Phase 3 Study for Large B-cell Lymphoma
EAST HANOVER, N.J., June 8 /PRNewswire/ -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1).Based on results from...
|
|
|
[Diagnosis in Oncology] Management of Anaplastic Large-Cell Lymphoma During Pregnancy
Journal of Clinical Oncology, 10.1200/JCO.2009.22.2042 This Article Google Scholar Social Bookmarking Fedro A.Peccatori1, Hatem A. Azim Jr2, Giancarlo Pruneri3, Gaia Piperno4, Paola R. [Diagnosis in Oncology] Management of Anaplastic ...
|
|
|
BGS Global Hospitals conducts first stem cell transplant for traumatic brain injury
BGS Global Hospitals has successfully used stem cells for a patient with traumatic brain injury.The stem cells were transplanted to the brain of the patient through a burr hole with navigation assisted surgery. The surgery...
|
|
|
In Diffuse, Large B-Cell Non-Hodgkin's Lymphoma, R-CHOP14 Is Similar to R-CHOP21: Presented at ASCO
my personal edition> non-hodgkin's lymphoma > news E-Mail this DGDispatch to a colleague DGDispatch ORLANDO, Fla -- June 6, 2009 -- A phase 3 trial comparing a 14-day cycle of rituximab with standard cyclophosphamide,...
|
|
|
Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the I
IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr.Naresh...
|
|
|
Taylor Scheibe, Miss First Coast High School, looks beyond cancer to future
Taylor Scheibe, Miss First Coast High School 2008-09.Photo submitted by Pam Greene Special to MyNorthsideSun.com At the age of 10, when most kids are carefree and preparing for middle-school, Northside resident Taylor Scheibe was...
|
